Guardant Executive and Leadership Team

AmirAli Talasaz, the Co-Founder & Co-Chief Executive Officer at Guardant, directs the overarching strategic vision for precision oncology diagnostics. Overseeing the integration of rare-cell analysis into clinical workflows, the Co-Founder & Co-Chief Executive Officer drives the expansion of testing services across North American and international markets. This leadership role involves constant collaboration with the Board to ensure long-term growth and technological advancement in cancer screening. By prioritizing innovation in liquid biopsy, AmirAli Talasaz directly impacts the ability of physicians to identify personalized treatment alternatives for patients. The Co-Founder & Co-Chief Executive Officer maintains a focus on scaling diagnostic capabilities to meet rising global demand. Through rigorous oversight of corporate objectives, Talasaz secures the market position of the organization as a leader in health services. This executive leadership ensures that diagnostic reports remain accurate, timely, and clinically relevant for oncology practices everywhere.

Mika Takaki, the General Manager and President at Guardant, directs the operational execution of diagnostic services across diverse market segments. Overseeing the commercialization of rare-cell testing, the General Manager and President ensures that physicians receive timely and actionable reports for cancer patients. This leadership role involves managing the supply chain and logistics required to support widespread diagnostic availability. By optimizing regional market penetration, Mika Takaki directly impacts the revenue growth and operational efficiency of the company. The General Manager and President coordinates with cross-functional teams to streamline the delivery of health services in competitive environments. Through rigorous management of operational workflows, Takaki secures the reliability of the diagnostic pipeline. This executive position requires constant monitoring of market trends to adjust service delivery models accordingly. The General Manager and President drives the expansion of diagnostic reach, ensuring that clinical teams have the necessary tools to identify effective treatment alternatives for patients.

Darya Chudova, the Chief Technology Officer at Guardant, architects the technical infrastructure supporting advanced rare-cell diagnostics. Managing the research and development pipeline, the Chief Technology Officer ensures the continuous evolution of testing platforms used to detect cancer markers. This role involves close coordination with data science teams to refine the accuracy of diagnostic reports provided to physicians. By optimizing laboratory automation and genomic sequencing processes, Darya Chudova directly enhances the efficiency of cancer patient care. The Chief Technology Officer oversees the implementation of scalable cloud solutions to handle complex diagnostic datasets across global operations. Through technical leadership, Chudova maintains the competitive edge of the company in the diagnostics industry. This position requires constant evaluation of emerging technologies to improve patient outcomes. The Chief Technology Officer drives the technical roadmap, ensuring that all diagnostic services meet the highest standards of precision and reliability for clinical applications.

Terilyn Monroe, the Chief People Officer at Guardant, directs the human capital strategy to support the mission of transforming cancer diagnostics. Overseeing talent acquisition and organizational development, the Chief People Officer ensures the alignment of workforce capabilities with the rapid growth of the company. This leadership role involves fostering a culture of innovation that attracts top-tier scientific and operational talent. By implementing comprehensive professional development programs, Terilyn Monroe directly impacts the retention and performance of teams dedicated to rare-cell diagnostics. The Chief People Officer manages internal communications and employee engagement initiatives across all regional offices to maintain a unified corporate identity. Through strategic workforce planning, Monroe supports the operational scale required to deliver testing reports to physicians worldwide. This executive function ensures that the organization maintains the necessary expertise to advance cancer care. The Chief People Officer drives initiatives that promote diversity, equity, and inclusion within the technical and administrative departments.